Abstract：Objective To analyze the anemia of 20 500 patients with malignant tumor. Methods The clinical data of 20 500 patients with malignant tumors admitted to Zhejiang cancer hospital from January to November 2018 were analyzed retrospectively, the incidence of different tumor associated anemia (CRA) was calculated. The severity of different CRA were analyzed. The age distribution and gender distribution of CRA were analyzed. Results The incidence of CRA in 20,500 cases was 23.7%. The highest incidence of CRA was gynecological tumors, followed by digestive and urinary system tumors. The incidence of head and neck tumors with anemia was the lowest. The severity of CRA was mostly 4,424 (91.1%) in grades 1-2, and 434 (8.9%) of CRA in grades 3-4. The age of CRA patients were mostly distributed from 50 to ＜70 years, accounting for 60.07%, followed by 30 to ＜50 years, accounting for 20.87%, and the youngest were less than 30 years, accounting for 1.26%. The incidence of CRA was higher in men than in women, the difference was statistically significant (P＜0.05). Conclusion The overall incidence of CRA is high, with grade 1-2 anemia as the predominant factor, the incidence of CRA is higher in men than in women.
Barni S，Cabiddu M，Guarneri P，et al.The risk for anemia with targeted therapies for solid tumors[J].Oncologist，2012，17（5）：715-724.
[2]
Heinz L，Simon B，Peter B，et al.The European cancer anemia survey（ECAS：a large，multinational，prospective survey defining the prevalence，incidence，and treatment of anemia in cancer patients[J].Eur J Cancer，2004，40：2293-2306.
[3]
Dicato M，plawny L，Diederich M.Anemia in cancer[J].Ann Oncol，2010，21（7）：167-172.
[4]
Qiu MZ，Yuan ZY，Luo HY，et al.Impact of pretreatment hematologic profile on survival of colorectal cancer patients[J].Tumour Biol，2010，31（4）：255-260.
[5]
Birgegard G，Gascón P，Ludwig H.Evaluation of anaemia in patients with multiple myeloma and lymphoma：finding of the European cancer anaemia survey[J].Eur J Haematol，2006，77（5）：378.
[6]
Qiu MZ，Xu RH，Ruan DY，et al.Incidence of anemia，leukocytosis and thrombocytosis in patients with solid tumors in China[J].Tumour Biol，2010，31（6）：633-641.
Kawada N，Moriyama T，Ichimaru N，et al.Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients[J].Clin Exp Nephrol，2009，13（4）：355-360.
[9]
Groopman JE，Itri LM.Chemotherapy -induced anemia in adults：incidence and treatment[J].Natl Cancer Inst，1999，91（19）：1616-1634.
Ludwig H，Strasser K.Symptomatology of anemia[J].Semin Oncol，2001，28（8）：7-14.
[13]
Sun C，Wang Y，Yao HS，et al.Allogeneic blood transfusion and the prognosis of gastric cancer patients：systematic review and meta-analysis[J].Int J Surg，2015，（13）：102-110.
[14]
Brown WM，Maxwell P，Graham AN，et al.Erythropoietin receptor expression in non-small cell lung carcinoma：a question of antibody specificity[J].Stem Cells，2007，25（3）：718-722.
[15]
Pedrazzoli P，Farris A，Del Prete S，et al.Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha[J].J Clin Oncol，2008，26（10）：1619-1625.
[16]
Spivak JL.Iron and the anemia of chronic disease：vindication for the Non-essential role of iron supplementation[J].Oncology，2011，25（5）：421-423.
[18]
Blackwell K，Gascón P，Sigounas G，et al.HuEPO and improved treatment outcomes：potential modes of action[J].Oncologist，2004，9（5）：41-47.
京公网安备 11010502046607号